UCB
A global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
The company is focused on CNS diseases, such as epilepsy, ADHD, memory problems, narcolepsy, Parkinson's disease and restless legs syndrome (RLS), and immunology such as allergies, ankylosing spondylitis, Crohn's disease, juvenile rheumatoid arthritis and RA, osteoporosis, psoriatic arthritis, respiratory disorders, rheumatoid arthritis and systemic lupus (SLE). Lead drugs include Cimzia (certolizumab pegol), Vimpat (lacosamide), Neupro (rotigotine) and Keppra (levetiracetam).
Latest UCB News & Features
10 June 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze